Novocure (NSDQ:NVCR) touted data today from the Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-diagnosed glioblastoma.
The analyses were presented at the American Society for Radiation Oncology’s 2017 annual meeting in San Diego.
The company’s EF-14 trial showed unprecedented five-year survival results in patients with newly-diagnosed GBM, Novocure reported. Patients treated with the Optune-chemotherapy combination experienced a significant extension of overall survival, without added toxicity, compared to patients treated with just temozolomide.
Patients who received the combination therapy were also able to maintain quality of life for longer than those treated with just temozolomide, Novocure touted.
“As the first treatment in more than 10 years to improve overall survival in newly diagnosed GBM, Optune has been proven to make a difference in the lives of GBM patients,” Dr. Eilon Kirson, Novocure’s chief science officer & head of R&D, said in prepared remarks. “It is great to have Optune as a topic of discussion in radiation oncology.”
Novocure’s Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields”, to inhibit cancer cell replication.
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
